- Home
- ADAP vs PDSB Comparison
ADAP vs PDSB Comparison
Compare ADAP & PDSB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ADAP
- PDSB
- Stock Information
- Founded
- ADAP 2008
- PDSB 2005
- Country
- ADAP United Kingdom
- PDSB United States
- Employees
- ADAP N/A
- PDSB N/A
- Industry
- ADAP Biotechnology: Pharmaceutical Preparations
- PDSB Biotechnology: Pharmaceutical Preparations
- Sector
- ADAP Health Care
- PDSB Health Care
- Exchange
- ADAP Nasdaq
- PDSB Nasdaq
- Market Cap
- ADAP 75.5M
- PDSB 72.2M
- IPO Year
- ADAP 2015
- PDSB N/A
- Fundamental
- Price
- ADAP $0.28
- PDSB $1.42
- Analyst Decision
- ADAP Buy
- PDSB Strong Buy
- Analyst Count
- ADAP 6
- PDSB 2
- Target Price
- ADAP $1.52
- PDSB $10.00
- AVG Volume (30 Days)
- ADAP 1.6M
- PDSB 713.0K
- Earning Date
- ADAP 05-13-2025
- PDSB 05-14-2025
- Dividend Yield
- ADAP N/A
- PDSB N/A
- EPS Growth
- ADAP N/A
- PDSB N/A
- EPS
- ADAP N/A
- PDSB N/A
- Revenue
- ADAP $179,639,000.00
- PDSB N/A
- Revenue This Year
- ADAP N/A
- PDSB N/A
- Revenue Next Year
- ADAP $52.49
- PDSB N/A
- P/E Ratio
- ADAP N/A
- PDSB N/A
- Revenue Growth
- ADAP 878.53
- PDSB N/A
- 52 Week Low
- ADAP $0.20
- PDSB $0.85
- 52 Week High
- ADAP $1.48
- PDSB $4.42
- Technical
- Relative Strength Index (RSI)
- ADAP 49.68
- PDSB 55.49
- Support Level
- ADAP $0.26
- PDSB $1.33
- Resistance Level
- ADAP $0.30
- PDSB $1.47
- Average True Range (ATR)
- ADAP 0.03
- PDSB 0.11
- MACD
- ADAP 0.00
- PDSB -0.01
- Stochastic Oscillator
- ADAP 54.53
- PDSB 43.08
About ADAP Adaptimmune Therapeutics plc
Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70, and others for multiple cancer types.
About PDSB PDS Biotechnology Corporation
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.